Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuan Cheng
Institutions:
Nanjing General Hospital of Nanjing Military Command,
Nanjing University
Observed institutions:
University of Science and Technology of China,
Nanjing University of Chinese Medicine,
Nanjing General Hospital of Nanjing Military Command,
81th Hospital of PLA,
Anhui Provincial Hospital,
Nanjing University
show all 6
ORCID:
0009-0003-0378-6221
Observed ORCID:
0009-0003-0378-6221
OpenAlex ID:
A5021229949
MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC
2025
·
Hai-Tao Yan
, Qing-Quan Zu
, et al.
·
Academic Radiology
·
12
Immune-Targeted Therapy with or without Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis (PVTT): A Multicenter Retrospective Study
2024
·
Ran You
, Yuan Cheng
, et al.
·
Biomedicines
·
8
Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon’s Perspective
2025
·
Xiao-Dong Zhu
, Lei Zhao
, et al.
·
Journal of Hepatocellular Carcinoma
·
7
PDF
Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma
2025
·
Jian-Lin Lu
, Yuan Cheng
, et al.
·
World Journal of Gastrointestinal Oncology
·
4
Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
2024
·
Xiao Shen
, Jin-Xing Zhang
, et al.
·
Journal of Hepatocellular Carcinoma
·
4
PDF
When Resectability Emerges After Systemic Therapy in Hepatocellular Carcinoma: A Proposed Response-Guided Consolidation Framework
2026
·
Yuan Cheng
, Kunlin Xie
·
Journal of Hepatocellular Carcinoma
·
2
PDF
Spontaneous Rupture of Hepatocellular Carcinoma: Pathogenesis, Clinical Management, Prognostic Factors, and Future Directions
2025
·
Yuan Cheng
, Feng Ye
, et al.
·
Journal of Hepatocellular Carcinoma
·
2
PDF
Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
2026
·
Yuan Cheng
, Jinguo Xia
, et al.
·
BMJ Open
·
1
PDF
Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial
2025
·
Yuan Cheng
, Yaodong Zhang
, et al.
·
BMJ Open Gastroenterology
·
1
PDF
Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC).
2023
·
Scott Kopetz
, Stefan Kasper
, et al.
·
Journal of Clinical Oncology
·
1
Adjuvant Sintilimab Plus Bevacizumab After Curative Resection of Spontaneously Ruptured Hepatocellular Carcinoma: Protocol for a Prospective, Exploratory, Single-Arm Study (CLEAR-2)
2026
·
Yuan Cheng
, Feng Ye
, et al.
·
Journal of Hepatocellular Carcinoma
PDF
Fatty acid degradation (FAD)–guided comprehensive therapy for unresectable hepatocellular carcinoma: A prospective phase II study (FAD-HCC-01).
2026
·
Decai Yu
, Binghua Li
, et al.
·
Journal of Clinical Oncology
NEO-ERA-01(CLEAP2507): A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors.
2026
·
Feng Cheng
, Yuan Cheng
, et al.
·
Journal of Clinical Oncology
Adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma: A prospective exploratory phase II study (CLEAR-2).
2026
·
Yongjun Chen
, Huichuan Sun
, et al.
·
Journal of Clinical Oncology
PDF
Fatty Acid Degradation (FAD) Subtype-Informed Treatment Allocation in Unresectable Hepatocellular Carcinoma (FAD-HCC-01): Protocol for a Prospective Multicentre Proof-of-Concept Study
2026
·
Yuan Cheng
, Binghua Li
, et al.
·
Journal of Hepatocellular Carcinoma
PDF
Author response for "X-ray Responsive Therapeutic Systems in Tumor Treatments"
2025
·
Runchen Sun
, Yuan Cheng
, et al.
·
Publons reviews and discussion
Show more works
View as search
Works count:
16
Citation count:
42
H-index:
4
I10-index:
1
Year
Topic
Type